CO2021015793A2 - Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 - Google Patents
Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33Info
- Publication number
- CO2021015793A2 CO2021015793A2 CONC2021/0015793A CO2021015793A CO2021015793A2 CO 2021015793 A2 CO2021015793 A2 CO 2021015793A2 CO 2021015793 A CO2021015793 A CO 2021015793A CO 2021015793 A2 CO2021015793 A2 CO 2021015793A2
- Authority
- CO
- Colombia
- Prior art keywords
- antagonist
- methods
- treating
- administering
- preventing asthma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención proporciona métodos para tratar o prevenir el asma y las afecciones asociadas en un paciente. Los métodos presentados en la invención comprenden administrar a un sujeto que lo necesita una composición terapéutica que comprende un antagonista de interleuquina-33 (IL-33), tal como un anticuerpo anti-IL-33. Los métodos presentados en la invención comprenden además administrar a un sujeto que lo necesita una primera composición terapéutica que comprende un antagonista de interleuquina-33 (IL-33), tal como un anticuerpo anti-IL-33, y una segunda composición terapéutica que comprende un antagonista del receptor de interleuquina-4 (IL-4R), tal como un anticuerpo anti-IL-4R.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841481P | 2019-05-01 | 2019-05-01 | |
| US201962848248P | 2019-05-15 | 2019-05-15 | |
| US201962898900P | 2019-09-11 | 2019-09-11 | |
| PCT/US2020/030824 WO2020223541A1 (en) | 2019-05-01 | 2020-04-30 | Methods for treating or preventing asthma by administering an il-33 antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021015793A2 true CO2021015793A2 (es) | 2021-11-30 |
Family
ID=70802932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0015793A CO2021015793A2 (es) | 2019-05-01 | 2021-11-24 | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210000949A1 (es) |
| EP (1) | EP3962515A1 (es) |
| JP (1) | JP2022530533A (es) |
| KR (1) | KR20220004708A (es) |
| CN (1) | CN113766931A (es) |
| AU (1) | AU2020266593A1 (es) |
| BR (1) | BR112021021195A2 (es) |
| CA (1) | CA3138306A1 (es) |
| CO (1) | CO2021015793A2 (es) |
| IL (1) | IL287275A (es) |
| MA (1) | MA55807A (es) |
| MX (1) | MX2021013427A (es) |
| SG (1) | SG11202111255YA (es) |
| TW (1) | TW202106334A (es) |
| WO (1) | WO2020223541A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ744109A (en) | 2012-08-21 | 2023-01-27 | Regeneron Pharma | Methods for treating or preventing asthma by administering an il-4r antagonist |
| WO2018045130A1 (en) | 2016-09-01 | 2018-03-08 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
| WO2020191346A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| DK4244252T3 (da) | 2021-08-27 | 2024-09-02 | Medimmune Ltd | Behandling af kronisk obstruktiv lungesygdom med et anti-interleukin-33-antistof |
| WO2023086887A1 (en) * | 2021-11-11 | 2023-05-19 | Regeneron Pharmaceuticals, Inc. | Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33) |
| TW202423972A (zh) | 2022-08-26 | 2024-06-16 | 英商梅迪繆思有限公司 | 使用抗介白素－３３抗體的氣喘治療 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| EP2041177B1 (en) | 2006-06-02 | 2011-12-14 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| MY158130A (en) | 2010-10-06 | 2016-08-30 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor )il-4r) antibodies |
| NZ744109A (en) * | 2012-08-21 | 2023-01-27 | Regeneron Pharma | Methods for treating or preventing asthma by administering an il-4r antagonist |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by adding an IL-4R antagonist |
| TWI784988B (zh) * | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| CR20190480A (es) * | 2017-04-21 | 2019-11-20 | Genentech Inc | Uso de antagonistas de klk5 para el tratamiento de una enfermedad |
-
2020
- 2020-04-30 AU AU2020266593A patent/AU2020266593A1/en active Pending
- 2020-04-30 CN CN202080032942.1A patent/CN113766931A/zh active Pending
- 2020-04-30 TW TW109114586A patent/TW202106334A/zh unknown
- 2020-04-30 WO PCT/US2020/030824 patent/WO2020223541A1/en active Application Filing
- 2020-04-30 MA MA055807A patent/MA55807A/fr unknown
- 2020-04-30 JP JP2021564454A patent/JP2022530533A/ja active Pending
- 2020-04-30 US US16/863,800 patent/US20210000949A1/en active Pending
- 2020-04-30 CA CA3138306A patent/CA3138306A1/en active Pending
- 2020-04-30 SG SG11202111255YA patent/SG11202111255YA/en unknown
- 2020-04-30 MX MX2021013427A patent/MX2021013427A/es unknown
- 2020-04-30 EP EP20727763.3A patent/EP3962515A1/en active Pending
- 2020-04-30 KR KR1020217038970A patent/KR20220004708A/ko unknown
- 2020-04-30 BR BR112021021195A patent/BR112021021195A2/pt unknown
-
2021
- 2021-10-14 IL IL287275A patent/IL287275A/en unknown
- 2021-11-24 CO CONC2021/0015793A patent/CO2021015793A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202111255YA (en) | 2021-11-29 |
| TW202106334A (zh) | 2021-02-16 |
| EP3962515A1 (en) | 2022-03-09 |
| BR112021021195A2 (pt) | 2022-03-03 |
| WO2020223541A1 (en) | 2020-11-05 |
| IL287275A (en) | 2021-12-01 |
| MX2021013427A (es) | 2022-01-31 |
| CN113766931A (zh) | 2021-12-07 |
| MA55807A (fr) | 2022-03-09 |
| US20210000949A1 (en) | 2021-01-07 |
| JP2022530533A (ja) | 2022-06-29 |
| KR20220004708A (ko) | 2022-01-11 |
| AU2020266593A1 (en) | 2021-11-11 |
| CA3138306A1 (en) | 2020-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| CO2020001823A2 (es) | Conjugados de citoquina para el tratamiento de enfermedades autoinmunes | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| CY1121360T1 (el) | Αναστολεις dna-pk | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| CL2021003477A1 (es) | Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8 | |
| CO2019005236A2 (es) | Métodos para tratar afecciones inflamatorias | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| ECSP18096095A (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos | |
| CL2019000245A1 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos. | |
| CR20160518A (es) | Compuestos para tratar atrofia muscular espinal | |
| CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
| CO2022001210A2 (es) | Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes | |
| EA201692334A1 (ru) | Кортикостероидные композиции для местного применения | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| CO2020005351A2 (es) | Uso de inhibidores de p38 para reducir la expresión de dux4 | |
| ECSP20000655A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| CO2020007601A2 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis |